Boston Scientific stock rises as BTIG reiterates Buy rating after strong Q3

Investing.com - Boston Scientific (NYSE:BSX), a $154.67 billion medical device maker trading near its 52-week high of $109.50, received a reiterated Buy rating and $132.00 price target from BTIG following its third-quarter earnings beat. According to InvestingPro, the company maintains a GREAT financial health score, with 15+ additional exclusive insights available to subscribers.

Boston Scientific reported revenue of $5.065 billion, representing 20.3% reported growth and 15.3% organic growth, exceeding consensus estimates of $4.969 billion. The company posted adjusted earnings per share of $0.75, above the consensus estimate of $0.71 and the high end of its guidance range of $0.70-$0.72. This performance aligns with the company’s strong 21.44% revenue growth over the last twelve months.

The Watchman segment was the standout performer with revenue of $512 million, $30 million above consensus, driven by continued concomitant uptake in the U.S. Electrophysiology revenue reached $865 million, exceeding consensus by $14 million, with a third of U.S. Farapulse accounts now using the integrated Nav catheter and Opal mapping system.

Boston Scientific achieved adjusted gross margin of 71.0% and adjusted EBIT margin of 28.0%, both 100 basis points better than expectations. The company’s Interventional Cardiology Therapies segment saw low double-digit growth in coronary therapies, while Endoscopy experienced double-digit growth in the U.S.

Following the strong results, Boston Scientific raised its 2025 guidance, now projecting organic sales growth of approximately 15.5% year-over-year (up from 14-15%), reported sales growth of approximately 20% (up from 18-19%), and adjusted EPS of $3.02-$3.04 (up from $2.95-$2.99). The company also expects approximately 100 basis points of year-over-year adjusted EBIT margin expansion. With a strong analyst consensus rating of 1.32 (Strong Buy), Boston Scientific’s detailed financial analysis and comprehensive research report are available on InvestingPro.

In other recent news, Boston Scientific reported its third-quarter 2025 earnings, surpassing analyst expectations. The company achieved an earnings per share (EPS) of $0.75, compared to the forecasted $0.71, which represents a 5.63% surprise. Additionally, Boston Scientific’s revenue reached $5.07 billion, exceeding projections by 2.01%. This strong performance was attributed to growth in operational sales and strategic product launches. Following the earnings report, Evercore ISI raised its price target for Boston Scientific from $110 to $113, maintaining an Outperform rating. The firm noted that previous investor concerns about potential share losses in the electrophysiology segment had been addressed with the positive earnings results. These developments highlight Boston Scientific’s continued strength across multiple business segments.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.